^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
tipapkinogene sovacivec (TG4001)
i
Other names: TG4001, TG-4001, MVA-HPV-IL2, RG3484, RO5217790, MVA virus vector encoding HPV types 16 E6 and E7 antigens and IL-2 adjuvant, RG 3484, RG-3484, RO 5217790, RO-5217790, TG 4001, R3484, R 3484, R-3484
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
European Organization for Research and Treatment of Cancer, Transgene
Drug class:
IL-2 stimulant, HPV-16 E6 protein inhibitor, HPV-16 E7 protein inhibitor
Related drugs:
8ms
Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers (clinicaltrials.gov)
P1/2, N=150, Active, not recruiting, Transgene | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
Enrollment closed • Trial completion date • Trial primary completion date • Metastases
|
Bavencio (avelumab) • tipapkinogene sovacivec (TG4001)
1year
Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers. (PubMed, Eur J Cancer)
TG4001 in combination with avelumab is safe, demonstrated antitumour activity in heavily pre-treated HPV16+ cancer patients, and is currently being evaluated in a randomised phase II trial in patients with incurable anogenital cancer and limited hepatic involvement.
Clinical • P1/2 data • Clinical Trial,Phase II • Journal • Combination therapy • Metastases
|
IFNG (Interferon, gamma) • IL2 (Interleukin 2)
|
Bavencio (avelumab) • tipapkinogene sovacivec (TG4001)
Share via
